Corline Biomedical Yönetim

Dr. Henrik Nittmar, Ph. D., has been the Chief Executive Officer of Corline Biomedical AB (publ) (alternate name Corline Systems AB) since 2008. Dr. Nittmar works as an Investment Manager for a select numb...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Lifvendahl	Non-Executive Director	2.8yrs	Veri yok	Veri yok
Lars Sunnanväder	Non-Executive Director	19.8yrs	Veri yok	9.82% SEK 16.9m
Gunilla Ekstrom	Independent Non-Executive Director	7.8yrs	SEK 105.00k	Veri yok
Adam Dahlberg	Chairman	19.8yrs	Veri yok	26.68% SEK 45.9m
Henrik Krook	Independent Non-Executive Director	7.5yrs	SEK 105.00k	Veri yok
Rutger Ploeg	Scientific Advisor	7.8yrs	Veri yok	Veri yok
Magnus Nilsson	Independent Non-Executive Director	4.8yrs	Veri yok	Veri yok

7.8yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CLBIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Corline Biomedical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Corline Biomedical AB, Annual General Meeting, May 14, 2021

Recent updates

Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.11 loss in 2Q 2023)

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

First quarter 2024 earnings released: kr0.078 loss per share (vs kr0.047 profit in 1Q 2023)

New major risk - Financial position

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Full year 2023 earnings released: kr0.084 loss per share (vs kr0.11 profit in FY 2022)

Corline Biomedical AB to Report Nine Months, 2024 Results on Nov 07, 2024

Corline Biomedical AB to Report Q1, 2024 Results on Apr 30, 2024

Second quarter 2023 earnings released: kr0.11 loss per share (vs kr0.041 profit in 2Q 2022)

New major risk - Share price stability

Price target increased by 30% to kr39.00

Investor sentiment improves as stock rises 31%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Corline Biomedical AB to Report First Half, 2023 Results on Aug 25, 2023

Third quarter 2022 earnings released: EPS: kr0.091 (vs kr0.097 loss in 3Q 2021)

We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Second quarter 2022 earnings released: EPS: kr0.041 (vs kr0.10 loss in 2Q 2021)

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Forecast breakeven date pushed back to 2024

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.15 loss in 2Q 2020)

Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.15 loss in 1Q 2020)

Corline Biomedical AB announced that it has received SEK 35.475 million in funding from M2 Asset Management AB (publ), HealthInvest Partners AB, and other investors

Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Full year 2020 earnings released: kr0.44 loss per share (vs kr0.59 loss in FY 2019)

New 90-day low: kr13.80

New 90-day low: kr13.85

Corline Biomedical AB, Annual General Meeting, May 14, 2021

New 90-day low: kr15.10

Third quarter 2020 earnings released: kr0.13 loss per share

First half earnings released

Corline Biomedical AB to Report Q4, 2020 Results on Jan 26, 2021

New 90-day low - kr17.05

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş